CSC-900 series (Cascade)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug NameCSC-900 series (Cascade)
Drug Alias Name5-HT 2a receptor antagonist/GlyT-1 inhibitor Cascade Therapeutics
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsGlycine transporter 1 inhibitors
TargetsSerotonin 2a (5-HT2a) receptorGlycine transporter 1
Therapy Area/IndicationsSchizophreniaSleep Wake Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCascade Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCascade Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsSchizophreniaSleep Wake Disorders

Other Information

ATC CodeN/A
Related LinksN/A